Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Cynata Therapeutics

Cynata Therapeutics

Cyanata Therapeutics is an Australian stem cell and regenerative medicine company that develops technology and products based on mesenchymal stem cells that have anti-inflammatory and immune-modulatory properties.

Cyanata Therapeutics is an Australian stem cell and regenerative medicine company founded in 2014. The company is developing a therapeutic stem cell platform technology called Cymerus, which is based on discoveries made at the University of Wisconsin-Madison (UWM). Cyanata's technology and product development is focused on the therapeutic potential of mesenchymal stem cells (or stromal cells) (MSCs), which have anti-inflammatory and immune-modulatory properties. The two inventors of Cyanata's Cymerus MSC technology are Professor Igor Slukvin and Dr. Maksym Vodyanik at University of Wisconsin – Madison.

Cynata Incorporated formed in 2011 as a California-registered company by Slukin and Vodyanik, in collaboration with Australian technology entrepreneur, Dr Ian Dixon. Cynata Incorporated was acquired by an ASX-listed company called EcoQuest Limited in 2013, which subsequently changed its name to Cynata Therapeutics Limited. The company is headquartered in Melbourne, Australia, and most of its operations are in the USA.

Technology and products

The Cymerus platform is based on mesenchymoangioblasts (MCAs), which are a precursor of mesenchymal stem (or stromal) cells (MSCs). Cynata’s proprietary technology utilizes induced pluripotent stem cells (iPSCs) derived from an adult donor as the starting material for generation of MCAs that are used for manufacturing the MSC therapeutic product. Cymerus technology is designed to achieve economic manufacturing of MSCs at commercial scale. The technology is claimed to allow virtually limitless quantities of MSCs to be produced without constantly seeking out fresh stem cell donors.

Cynata Therapeutics was issued a notice from the State Intellectual Property Office of the People’s Republic of China (SIPO) in February 2020, regarding a decision to grant a patent for its Cymerus mesenchymal stem cell (MSC) technology entitled “Colony Forming Medium and Use Therof.” The patent encompasses the manufacturing process that is part of the development of off-the-shelf therapeutic stem cell products.

MSC products

Fujufilm Corporation reached an agreement with Cyanata in September 2021 to conduct clinical and commercial manufacturing regenerative medicine products using iPS cells. Cynata used iPS cells supplied by Fujifilm Cellular Dynamics to develop products including CYP-001, which targets graft-versus-host disease (GvHD) and CYP-004 for osteoarthritis. Fujifilm made a minority investment in Cynata in 2017 and acquired the rights for development and manufacturing and sales of CYP-001 in 2019.

Cyanata has products in Phase 3 clinical trials that treat osteoarthritis, respiratory failure, and diabetic food ulcers. Cymerus technology is used in preclinical models of diseases for critical limb ischemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS), and cytokine release syndrome.


September 14, 2020
The world’s first human clinical trial of an iPSC-derived MSC cell was Cynata’s CYP-001


Further Resources


Overcoming the Challenges of Manufacturing Therapeutic Mesenchymal Stem Cells



Golden logo
By using this site, you agree to our Terms & Conditions.